Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 196
- 试验地点
- 2
- 主要终点
- Change in coronavirus disease 19 (COVID19) antibody titers over time
研究概览
简要总结
The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision making in this patient population.
详细描述
This will be a prospective, observational cohort study consisting of individuals with autoimmune diseases who are undergoing treatment with anti-CD20 medications at the time they receive a vaccine against COVID-19. Control groups will include healthy individuals, individuals with autoimmune diseases on other immunomodulators, and individuals with autoimmune diseases not on immunotherapy.
Participants will undergo serial blood draws and saliva collections at prespecified time points surrounding vaccination. A subset of agreeable participants will undergo skin biopsy within days of the first vaccination, with the option to repeat skin biopsy after the second vaccination. Additional blood, saliva and skin biopsy specimens may be obtained after booster vaccinations or after known COVID19 infections .
Specimens collected will be used for studies aimed at (1) understanding the pathobiology of neurologic/inflammatory/immune diseases and the immunologic response to COVID-19 vaccination, (2) identifying how and why treatments used for neurologic/immune diseases may impact the effectiveness of vaccination, and (3) identifying dermatologic manifestations of the immunologic response to the COVID-19 mRNA vaccine.
The investigators are investigating both the production of antibodies against the virus over time and deeply interrogating the T-cell response to vaccination using methods that measure T-cell reactivity to the COVID-19 virus, including single cell RNA sequencing.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects with neurologic/immunologic condition:
- •at least 18 years of age
- •Known diagnosis of autoimmune neurologic disease (e.g. multiple sclerosis (MS), neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG) -associated disorder) or autoimmune blistering disease (AIBD).
- •Treated with an anti-CD20 (rituximab, ocrelizumab) medications for >6 months at the time of vaccination (B-cell depletion therapy, BCDT)
- •On no immunomodulatory therapy for their autoimmune condition for >6 months at the time of vaccination
- •Treated with a non-BCDT immunotherapy
- •No relapse of neurologic/immunologic disease for >6 months prior to the time of enrollment
- •Subject is eligible and willing to receive COVID-19 vaccination in accordance with local and national guidelines, or subject intends to receive booster COVID-19 vaccination in accordance with recommendations from their primary medical team.
- •No active skin condition (e.g. open sores) preventing blood draw
- •Healthy Controls:
- •at least 18 years of age
- •No evidence of neurological/immunologic disease/illness/condition
- •Subject is eligible and willing to receive COVID-19 vaccination in accordance with local and national guidelines, or subject intends to receive booster COVID-19 vaccination in accordance with recommendations from their primary medical team.
- •No active skin condition (e.g. open sores) preventing blood draw/skin biopsy
排除标准
- •Use of high dose steroids for treatment of neurologic/immunologic disease within 1 month of COVID-19 vaccination
- •Anti-CD20 B-cell depleting therapy infused within 2 weeks of first study visit
- •Inability to comply with the requirements of the protocol, in the opinion of the primary investigator
研究组 & 干预措施
Healthy control
Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
干预措施: COVID19 vaccine (Biological)
Disease control
Disease controls (individuals with a qualifying autoimmune condition, but not treated with any immunomodulator).
Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
干预措施: COVID19 vaccine (Biological)
B-cell depleted
Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with B-cell depleting anti-CD20 monoclonal antibodies.
Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
干预措施: COVID19 vaccine (Biological)
Other immunomodulator
Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with a non-CD20 monoclonal antibody immunomodulator to treat their disease.
Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
干预措施: COVID19 vaccine (Biological)
结局指标
主要结局
Change in coronavirus disease 19 (COVID19) antibody titers over time
时间窗: Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines
COVID 19 spike and neutralizing antibody titers will be monitored serially
Change in severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) specific T-cell activation over time
时间窗: Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines
Flow cytometry characterizing immunophenotype of SARS-CoV2 specific T cells
次要结局
- Skin biopsy analysis(7 days post vaccine 1; 7 days post vaccine 2; 4 days post booster (all timepoints optional))
- Measurement of COVID19 antibodies in saliva(Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines)
- Immune analysis(Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines)
- Changes in patient reported outcomes: COVID history(Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines)
- Change in patient reported outcomes: patient reported disability steps(Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines)
- Change in patient reported outcomes: overall symptoms(Baseline, 2 weeks post vaccine 1, pre-vaccine 2, 1 week post vaccine 2, 6 months post vaccine 2; pre- and 2 week post any additional vaccines)